Jeng-Sen Tseng

肺癌、胸腔醫學

臨床與基礎的轉譯醫學、良醫講堂

台中榮總胸腔內科主治醫師 2010~今

1. 期刊論文

1. Tseng CH, Tsuang BJ, Chiang CJ, Ku KC, Tseng JS, Yang TY, Hsu KH, Chen KC, Yu SL, Lee WC, Liu TW, Chan CC, Chang GC. The relationship between air pollution and lung cancer in nonsmokers in Taiwan. J Thorac Oncol 2019; 14:784-92. (SCI)

2. Su KY, Tseng JS, Liao KM, Yang TY, Chen KC, Hsu KH, Yang PC, Chang GC. Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. PLOS One 2018; in press. (SCI)

3. Hsu KH, Huang YH, Tseng JS, Chen KC, Ku WH, Su KY, Chen JJ, Chen HW, Yu SL, Yang TY, Chang GC. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung cancer 2018; in press. (SCI)

4. Tseng JS, Yang TY, Wu CY, Ku WH, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Chang GC. Characteristics and predictive value of PD-L1 status in real world non-small cell lung cancer patients. J Immunother 2018; 41:292-9. (SCI)

5. Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, Chen JJW, Chen HW, Yu SL, Yang TY, Chang GC. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res Treat 2018; 50:1294-303. (SCI)

6. Tseng JS, Yang, TY, Chen KC, Hsu KH, Huang YH, Huang YH, Su KY, Yu SL, Chang GC. Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib Treatment. Cancer Res Treat 2018; 50:1164-74. (SCI)

7. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM, Huang MS, Ho CC, Yu CJ, Tsai YH, Chen JS, Chou TY, Tsai MH, Chen HY, Su KY, Chen JJ, Chen HW, Yu SL, Liu TW,  Chang GC. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget 2017; 8:98384-93. (SCI)

8. Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer 2017; 104:58-64. (SCI)

9. Tseng JS, Su KY, Yang TY, Chen KC, Hsu KH, Chen HY, Tsai CR, Yu SL, Chang GC. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M. Oncotarget 2016; 7:48059-69. (SCI)

10. Hsu KH, Tseng JS, Wang CL, Yang TY, Tseng CH, Chen HY, Chen KC, Tsai CR, Yang CT, Yu SL, Su KY, Yu CJ, Ho CC, Hsia TC, Wu MF, Chiu KL, Liu CM, Yang PC, Chen JJ, Chang GC. Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget 2016; 7:53299-308. (SCI)

11. Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, Wang CL, Chen CY, Yen S-, Chiu CH, Huang MS, Yu CJ, Tsai YH, Chen JS, Tsai CM, Chou TY, Lin KC, Tsai MH, Lee WC, Ku HY, Liu TW, Yang TY, Chang GC. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget 2016; 7:46628-35. (SCI)

12. Chan MC, Tseng JS, Hsu KH, Shih SJ, Yi CY, Wu CL, Kou YR. A minimum blood glucose value ≤ 120mg/dl under glycemic control is associated with increased 14-day mortality in non-diabetic ICU patients with sepsis and stress hyperglycemia. J Crit Care 2016; 34:69-73. (SCI)

13. Huang YH, Wu CI, Tseng JS, Chen KC, Chang GC. Pulmonary Talcosis in an Intravenous Drug Abuser: A Case Report and Literature Review. Thorac Med 2016; accepted.  

14. Chen HY, Liu CH, Chang YH, Yu SL, Ho BC, Hsu CP, Yang TY, Chen KC, Tseng JS, Hsia JY, Chuang CY, Chen CY, Chang CS, Li YC, Li KC, Chang GC, Yang PC. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma. Oncotarget 2016; 7:9017-25. (SCI)

15. Huang YH, Hsu KH, Tseng JS, Chen KC, Su KY, Chen HY, Chang CS, Chen JJ, Yu SL, Yang TY, Chang GC. Predilection of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients. J Thorac Dis 2016; 8:86-92. (SCI)

16. Tseng CH, Chen KC, Hsu KH, Tseng JS, Ho CC, Hsia TC, Su KY, Wu MF, Chiu KL, Liu CM, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Yang TY, Chang GC. Different EGFR mutation profiles between the upper and lower lobes in lung adenocarcinoma. Carcinogenesis 2016; 37:157-162. (SCI)

17. Wang YR, Tseng CH, Chang GC, Hsu JY, Tseng JS (*). Pulmonary Cement Embolism: a case report and review of the literature. Thorac Med 2016; 31:55-9.

18. Tseng JS, Wang CL, Yang TY, Chen CY, Yang CT, Chen KC, Hsu KH, Tsai CR, Chang GC. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer 2015; 90:472-6. (SCI)

19. Hsu KH, Ho CC, Hsia TC, Tseng JS (**), Su KY, Wu MF, Chiu KL, Yang TY, Chen KC, Ooi H, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Chang GC. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLOS One 2015; 10:e0120852. (SCI)

20. Chen HY, Yu SL, Ho BC, Su KI, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chang YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang CY, Yuan SS, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ, Chen KY, Tsai YH, Su WC, Chen HW, Chen JJ, Chen CJ, Chang GC, Yang PC, L CK. R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with Medical actionability. J Clin Oncol 2015; 33:2303-10. (SCI)

21. Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Chen JJ, Chang GC. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2015; 10:603-10. (SCI)

22. Chan MC, Tseng JS, Chiu JT, Hsu KH, Shih SJ, Yi CY, Wu CL, Kou YR. Lower plateau pressure is still associated with lower mortality when it is below 30 cm H2O in septic patients with acute respiratory failure. Respir Care 2015; 60:12-20. (SCI)

23. Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, Chang GC. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. PLOS One 2014; 9:e107160. (SCI)

24. Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Prior EGFR tyrosine kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma. Onco Targets Ther. 2014; 7:799-805. (SCI)

25. Chen IH, Wang YL, Hsu ST, Hsu JY, Tseng JS (*). Pulmonary benign metastasizing leiomyoma: a case report and review of the literature. Thorac Med 2014; 29:371-6.

26. Chien WL, Tseng JS (*). Pulmonary aspergillosis in an immunocompetent patient. Braz J Infect Dis. 2013; 17:375-6. (SCI)

27. Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC. Retrospective Study of Erlotinib in Patients with Advanced Squamous Lung Cancer. Lung Cancer. 2012; 77:128-33. (SCI)

28. Tseng JS, Wu CY, Cheng HF, Li PS, Li JR, Lee BJ. A 76-year-ol man with progressive lower back pain and right thigh swelling. Emerg Med J. 2012; 29:86-7. (SCI)

29. Wu-CL, Tseng JS. Optimizing management of ventilator-associated pneumonia. Taiwan Crit Care Med. 2008; 9:110-6.

30. Tseng JS, Chan MC, Hsu JY, Kuo BI, Wu CL. Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology. 2008; 13:505-9. (SCI)

31. Tseng JS, Lee YC, Pan HC, Chang MH. Motor neuron disease-like syndrome secondary to trapped fourth ventricle and obstruction of cerebrospinal fluid pathway. Clin Neurol Neurosurg. 2007; 109:383-7. (SCI)